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Abstract Gene expression of synoviocytes stimulated with
tumor necrosis factor-K (TNFK) was studied by macroarray
analysis to elucidate the cellular response and identify new
biological functions of known and unknown genes. 10 035 cDNA
clones were used to make cDNA macroarrays of representative
genes. Synoviocytes expressed large amounts of fibronectin and
collagen mRNA. Statistical analysis of the macroarray data
revealed 26 genes, including six new genes, which underwent
significant alteration of gene expression in response to TNFK
stimulation. These findings suggest that the synoviocyte response
to TNFK stimulation forms the basis of development of various
aspects of the pathophysiology of rheumatoid arthritis. ß 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Tumor necrosis factor-K (TNFK), a pro-in£ammatory cyto-
kine, has been thought to be an important mediator of in-
£ammation such as rheumatoid arthritis (RA) [1]. Synovial
tissue in£ammation is caused by TNFK secreted by lympho-
cytes. For example, interleukin 8 (IL8), the level of which
increases in synoviocytes in response to TNFK, induces fur-
ther in¢ltration by lymphocytes [2]. Thus, TNFK signaling has
been looked upon as a therapeutic target molecule of RA.
However, the cellular response of synovial cells to TNFK
remains to be fully investigated.
cDNA array analysis is a useful method for e⁄ciently ex-
ploring the functions of uncharacterized genes in addition to
known genes by relating the expression pattern of one gene to
those of others. Many types of cDNA arrays have been pro-
posed and applied to expression pro¢ling, e.g. PCR-ampli¢ed
DNA spots on a slide glass or a nylon membrane and high-
density colony grids on a membrane [3^5].
The fundamental features of massive data acquisition, min-
iaturization, multiplexing and automation of cDNA microar-
ray assays augment the expression pro¢ling data obtained
with slide glass-based cDNA microarrays. cDNA microarray
analysis has developed a new concept of cellular diagnosis
based on the clustering of gene expression patterns [6,7]. Anal-
ysis using nylon membrane-based cDNA macroarrays is a
conventional method among cDNA array analyzing systems.
High-density colony grids are the most conventional cDNA
macroarray.
In this study, we used cDNA macroarray analysis to inves-
tigate gene expression of synoviocytes with the goal of eluci-
dating the total cellular response to TNFK. The macroarrays
were prepared using non-redundant genes, including novel
genes [8]. This study has revealed new biological functions
of both known and novel genes. These results suggest involve-
ment of a synoviocyte response in the development of various
aspects of the pathophysiology of RA.
2. Materials and methods
2.1. Sequencing
Sequencing of the 5P-end of the cDNA insert was performed using a
Big Dye Terminator Cycle Sequencing kit and ABI377XL sequencer
(Applied Biosystems). The sequencing primer was 5P-TACGGAA-
GTGTTACTTCTGC-3P. For full-length insert cDNA sequencing,
speci¢c primers of the cDNA were designed and used.
2.2. Preparation of macroarrays
A non-redundant gene set was used for the macroarray analysis.
5P sequences of 55 618 clones were clustered into 17 699 groups using
computer programs. This gene set included 2885 known genes and
7150 unknown/homologous genes.
Both high-density colony and PCR-ampli¢ed cDNA macroarrays
were prepared. High-density colony macroarrays were prepared as
described previously [9]. Macroarrays spotted with PCR-ampli¢ed
insert clones were prepared as follows. Plasmid inserts were ampli¢ed
using 5P-TACGGAAGTGTTACTTCTGC-3P and 5P-TGTGGGA-
GGTTTTTTCTCTA-3P as sequencing primers. PCR cycles were per-
formed (10 cycles of 20 s at 98‡C for denaturation and 6 min at 60‡C
for annealing and elongation, followed by 20 cycles of 20 s at 98‡C for
denaturation and 3 min at 60‡C for annealing and elongation) using a
GeneAmp PCR System 9600 (Perkin Elmer). The amount of each
PCR product was evaluated on the basis of the intensity of the
band detected by gel electrophoresis. Then, the PCR samples were
spotted onto nylon membranes (11U7.5 cm) in a 3U3 format using
a Biomek 2000 Robotics Workstation (Beckman) to yield 3456 spots
per membrane.
2.3. Probe preparation for macroarray
Synoviocyte total RNA (5 Wg) or 1.5 Wg of human tissue poly A
RNA (Clontech) was combined with 50 pmol oligo(dT) in a total
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volume of 6 Wl, heated to 65‡C for 5 min and then cooled on ice. 5 Wl
of dATP (3000 Ci/mmol), 1 Wl of 0.1 M DTT, 4 Wl of ¢rst-strand
bu¡er (Gibco BRL), 2 Wl of dNTPs (10 mM each of dTTP, dGTP and
dCTP, and 37 WM dATP), 1 Wl of 40 U/Wl RNASEOUT (Gibco BRL)
and 1 Wl of Thermoscript RT (Gibco BRL) were then added. Each
sample were then incubated at 45‡C for 1.5 h to generate 33P-labeled
cDNA. 80% of the radioactive label was incorporated into the cDNA
probe. The length of the probe ranged from 0.5 to 3.5 kb, as shown by
1% alkaline agarose gel electrophoresis and autoradiography.
2.4. Macroarray hybridizations
The labeled probe was denatured at 98‡C for 5 min and then added
to 9 ml of hybridization solution pre-warmed to 65‡C. Pre-hybridiza-
tion with 1 pmol/ml oligo(dT) and 10 Wg/ml denatured Cot-1 DNA
(Gibco BRL) was performed at 65‡C for 3 h, followed by hybridiza-
tion at 65‡C for 12 h in the hybridization solution. After hybridiza-
tion, the membranes were washed twice in 2U SSC, 1% SDS at room
temperature for 20 min. The membranes were then washed three times
with 0.1U SSC, 1% SDS at 65‡C for 20 min.
2.5. Macroarray data analysis
Imaging plates exposed to macroarrays at room temperature for 4 h
were scanned with a BAS2000 system (Fuji Photo Film Co., Ltd.).
After image acquisition, the scanned images were analyzed using the
ArrayGauge software (Fuji Photo Film Co., Ltd.) for quanti¢cation
of the radioactivity of each spot. Background due to non-speci¢c
binding of probes to the membrane was subtracted from the signal
intensity of each spot. The data were statistically analyzed.
2.6. Cell culture
Human ¢broblast-like synoviocytes (Cell Applications, Inc.) were
cultured in Synoviocyte Growth Medium (Cell Applications, Inc.) in
an atmosphere of 95% air and 5% CO2 at 37‡C. After the cells had
grown con£uently, the medium was changed to fresh medium with or
without 10 Wg/ml human recombinant (E. coli) TNFK (Boehringer-
Mannheim). The total RNA was isolated using an S.N.A.P.1 total
RNA extraction kit (Invitrogen Inc.).
2.7. Northern blot analysis and RNA dot-blot analysis
Alpha cardiac actin, IL8, TFPI2 and FLJ10143 probes were labeled
with dCTP (3000 Ci/mmol) using a BcaBEST labeling kit (Takara
Shuzo Co., Ltd.).
For RNA dot-blots, 1 Wg of human tissue poly A RNA (Clontech)
was dotted onto a nylon membrane (Boehringer-Mannheim). For
Northern blots, 2 Wg of total RNA was fractionated on 1% form-
aldehyde-agarose gel and blotted onto nylon membranes. The RNA
on the membranes was ¢xed using a Stratalinker UV crosslinker
(Stratagene). The membranes were hybridized with the probes at
68‡C for 12 h using ExpressHyb1 hybridization solution (Clontech).
The membranes were washed twice with 2U SSC, 1% SDS at room
temperature for 20 min, followed by three times with 0.1U SSC, 1%
SDS at 65‡C for 20 min. The membranes were then exposed to auto-
radiography ¢lm with an intensifying screen at 380‡C.
3. Results
3.1. Evaluation of macroarray data
First, we compared two kinds of cDNA macroarray sys-
tems made with 3456 high-density colony grids and PCR-am-
pli¢ed cDNA spots. In the high-density colony grid macro-
array, 10% of the spots showed over three-fold variation
between duplicate macroarrays, indicating poor reproducibil-
ity (Fig. 1A). In contrast, with the PCR-ampli¢ed cDNA
macroarrays only 0.3% of the spots showed over three-fold
variation between duplicate macroarrays (Fig. 1B). In addi-
tion, the signal intensity of each spot between the duplicate
PCR-ampli¢ed cDNA macroarrays showed less than 1.9-fold
variation for 95% of the total spots, showing relatively high-
quality reproducibility.
PCR-ampli¢ed alpha cardiac actin cDNA spotted on eight
nylon membranes was hybridized with probe prepared from
mRNA from eight di¡erent tissues (Fig. 1C). These results
agreed with the results of RNA dot-blot hybridization with
the alpha cardiac actin probe (Fig. 1D), showing the reliability
of the macroarray data as a tool for gene expression analysis.
The signal intensity of the spot was increased by increasing
the amount of probe used (data not shown), indicating a
correlation between the signal intensity and amount of probe
hybridized. Thus, 10 035 cDNAs were ampli¢ed and spotted
onto three nylon membranes to make a set of PCR-ampli¢ed
macroarrays. Each membrane had nine spots of L-actin
cDNA as controls.
3.2. Macroarray analysis of the di¡erential expression of genes
Human synoviocytes were cultured for 24 h in serum-con-
taining medium with or without TNFK. The total RNA was
used for hybridization with three sets of macroarrays. AN-
OVA statistical analysis of the control spots showed no dif-
ferential hybridization among membranes within a set of
macroarrays (data not shown), indicating uniform hybridiza-
tion among membranes. Then, the signal of each spot was
normalized based on the assumption that the sum of all
spots within a set of macroarrays would be constant between
the membranes hybridized with the probe for normal syno-
viocytes and the probe for TNFK-stimulated synoviocytes.
The mean and the standard deviation were calculated for
each spot. Three assays was performed to calculate these
values. For each sample, spots with poor quality (standard
deviationsmean) were not used. As a result, 9655 genes
Fig. 1. Macroarrays for the analysis of gene expression. A,B: Dupli-
cate membranes of 3456 spots representing each gene were hybrid-
ized with 33P-labeled cDNA probes. The signal intensity of each
spot on the ¢lters was plotted. The two lines in the ¢gure show
three-fold variation in the signal intensity from each ¢lter. A: High-
density colony grid macroarrays. B: PCR-ampli¢ed cDNA macroar-
rays. C: PCR-ampli¢ed alpha cardiac actin cDNA was spotted and
hybridized with cDNA probes from tissues (H: heart, L: lung, P:
pituitary gland, T: thymus, B: brain, K: kidney, Li: liver, S:
spleen). Each bar shows the intensity of the spot. D: RNA dot-blot
analysis of alpha cardiac actin. The inset is the autoradiogram of
the hybridization. Each bar shows the intensity of the spot.
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were selected for further analysis, and 9079 (94% of the
analyzed genes) genes showed intensity which was within
two-fold variation between the normal and stimulated syno-
viocytes (Fig. 2A). Genes with over three-fold variation be-
tween the normal and stimulated synoviocytes totaled 162
(1.7% of the analyzed genes), suggesting the validity of the
above assumption. Twenty-six genes, including six unknown
genes, showed over three-fold variation, with statistical sig-
ni¢cance, between the normal and stimulated synoviocytes
(Table 1).
The 26 genes were categorized based on the ontology of
their molecular function. Increased expression was observed
in 12 of these known genes and in eight unknown genes. Table
1 also lists some examples of genes showing constant expres-
sion between the normal and stimulated cells. The top three
known genes showing higher signal intensities of 1012, 896
and 758, respectively, were ¢bronectin 1, vimentin and pre-
pro-alpha1(I) collagen in synoviocytes analyzed using the
cDNA macroarrays.
3.3. Con¢rmation of gene expression by Northern blotting
To validate the above results, Northern blotting was per-
formed for two known genes, IL8 and TFPI2, and an unchar-
acterized gene as examples. Expression of IL8, known to be
increased by TNFK [10], was shown by the macroarray anal-
ysis to be elevated 65.8-fold in synoviocytes stimulated with
TNFK. Northern blot analysis yielded a similar result. IL8
expression was not observed in the normal synoviocytes but
was found in the synoviocytes stimulated with TNFK, indicat-
ing an almost all-or-nothing phenomenon (Fig. 2B).
The macroarray analysis showed that expression of TFPI2
was elevated 10.2-fold in synoviocytes stimulated with TNFK,
and Northern blot analysis gave a similar result (Fig. 2B). The
normal synoviocytes expressed TFPI2, and this expression
was increased in the synoviocytes stimulated with TNFK.
The macroarray analysis showed that expression of
FLJ10143, a new gene, was elevated 9.5-fold in synoviocytes
stimulated with TNFK, and this result was con¢rmed by
Northern blot analysis (Fig. 2C). The mRNA size was about
2.1 kb. The normal synoviocytes expressed FLJ10143, and
this expression was increased in the synoviocytes stimulated
with TNFK.
3.4. Full sequencing analysis of novel clones revealed by
macroarray analysis
FLJ10143, whose expression was increased 9.5-fold in the
stimulated cells, was a novel gene of 1694 bp encoding 468 aa
(GenBank accession No. AK001005) with two immunoglob-
ulin domains in the middle of the sequence and a membrane-
spanning region at the C-terminal region (Fig. 3A). The high-
est similarity (29%) was with poliovirus receptor. Alignment
of FLJ10143 with the human genome sequence revealed the
presence of an NF-UB binding motif at the 3130 base site
from the 5P-end of FLJ10143 on the genome sequence (data
not shown).
FLJ11467, increased three-fold in the stimulated cells, was a
novel gene of 1220 bp encoding 365 aa (GenBank accession
No. AK021529) (Fig. 3B). It showed no signi¢cant similarity
with known proteins. An amino acid sequence motif search
revealed the presence of a prenylation motif at the C-terminal
position.
FLJ14427, increased 3.1-fold in the stimulated cells, was a
novel gene of 1074 bp encoding 208 aa (GenBank accession
No. AK027333) (Fig. 3C). There was no signi¢cant similarity
with known proteins, and no amino acid domain/motif.
FLJ14492, increased 3.5-fold in the stimulated cells, was a
novel gene of 2322 bp encoding 619 aa (GenBank accession
No. AK027398) with 16 zinc ¢nger C2H2-type domains and
an ATP/GTP-binding site motif (Fig. 3D). There was the
highest similarity (43%) with zinc ¢nger protein ZNF135.
FLJ14834, decreased 3.3-fold in the stimulated cells, was a
novel gene of 1836 bp encoding 150 aa (GenBank accession
No. AK027740) (Fig. 3E). There was no signi¢cant similarity
with known proteins, and no amino acid domain/motif. Align-
ment of FLJ14834 with the human genome sequence revealed
the presence of an NF-UB binding motif at the 3156 base site
from the 5P-end of FLJ14834 on the genome sequence (data
not shown).
FLJ10500, increased 3.3-fold in the stimulated cells, en-
coded a novel mRNA of 3086 bases (GenBank accession
No. AK001362). The amino acid coding region was not able
to be determined from this sequence since there was no sig-
ni¢cant open reading frame.
Fig. 3F summarizes the predicted domains, motifs and
membrane-spanning regions of these novel proteins.
Fig. 2. Macroarray analysis of gene expression in synoviocytes stimulated with TNFK. Synoviocytes were cultured in medium with or without
10 Wg/ml TNFK for 24 h. A: The expression of genes was analyzed using PCR-ampli¢ed cDNA macroarrays. The mean of the triplicate signal
intensity of each gene was plotted. The two lines in the ¢gure show two-fold variation in the signal intensity from each ¢lter. B: Northern blot
analysis of IL8 and TFPI2. 2 Wg per lane of mRNA were subjected to denaturing-gel electrophoresis and blotted onto a nylon membrane. C:
Northern blot analysis of FLJ10143. Arrowhead indicates the bands of FLJ10143.
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4. Discussion
Among 9655 analyzed genes, 162 (1.7%) genes showed over
three-fold variation between synoviocytes with or without
TNFK stimulation. Since 1.7% is larger than 0.3%, the per-
centage from control analysis for evaluation of this cDNA
macroarray analysis, the 162 genes were surmised to include
genes with signi¢cantly altered expression. Twenty-six such
genes were con¢rmed by statistical analysis of the variation.
Northern blot analysis validated these di¡erential expressions.
These results suggested that few genes had their expression
a¡ected by TNFK stimulation of synoviocyte.
Fig. 3. Amino acid sequences of FLJ clones showing altered expres-
sion in synoviocytes stimulated with TNFK. Bold amino acids indi-
cate the probable domain predicted by PFAMA. Underlined amino
acids indicate the probable motif predicted by PROSITE. Each mo-
tif and domain accession number is shown in the following brack-
ets. Boxed amino acids indicate the membrane-spanning region pre-
dicted by SOSUI. A: FLJ10143 protein. The aa locations [205^285]
and [318^384] encode the immunoglobulin domains (PF00047). The
aa location [380^386] encodes an immunoglobulin major histcom-
patibility complex motif (PS00290). B: FLJ11467 protein. The aa
location [362^365] encodes a prenylation motif (PS00294). C:
FLJ14427 protein; D: FLJ14492 protein. The aa locations [22^44],
[84^106], [112^134], [140^162], [168^190], [196^218], [224^246], [252^
274], [280^302], [308^330], [336^358], [364^386], [392^414], [516^
538], [544^566] and [572^594] encode zinc ¢nger C2H2-type domains
(PF00096). The aa location [169^176] encodes ATP/GTP-binding
site motif A (PS00017). E: FLJ14834 protein; F: illustrations of aa
sequences of A^E. Open box: domain; hatched box: motif ; closed
box: membrane-spanning region.
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Our expression pro¢ling data for synoviocytes stimulated
with TNFK are consistent with the ¢ndings of previous re-
ports. It was reported that IL8 was not expressed in normal
synoviocytes but was augmented 26-fold in synoviocytes
stimulated with TNFK [10,11]. ICAM1, TNFAIP3, ALDR1
and PAI2 were reported to be induced by TNF stimulation of
synoviocytes [12], endothelial cells [13], liver cells [14] and
melanoma [12], respectively. It was reported that TNFK in-
creased the expression of a PLOD-like gene in the HTB-94
cell line, which is of human origin and maintains a chondro-
cytic phenotype [15]. These gene expression changes induced
by TNFK were detected by our macroarray analysis. In addi-
tion to those reported genes, we found altered expression of
other known genes (Table 1).
The amount of RNA for each gene expressed in cells could
be an important factor in addition to the fold alteration of
gene expression for the expression of the cellular functions. It
is not easy to compare the amount of RNA between di¡erent
genes by macroarray analysis. Thus, we roughly compared the
amounts of RNA among genes under the assumption that the
probe activity and hybridization e⁄ciency were comparable
for each gene. Synoviocytes expressed large amounts of ¢bro-
nectin and collagen in this cDNA macroarray analysis. These
results agree with the in vivo study reported by Wolf et al.
that showed enhanced deposition of ¢bronectin and collagen
in synovial £uid [16]. Therefore, the main function of syno-
viocytes seems to be the production of these extracellular ma-
trix (ECM) proteins. Among the analyzed genes, IL8 showed
the most signi¢cant change in expression by TNFK stimu-
lation. TFPI2 and PAI2 also showed signi¢cantly increased
expression. The relative amounts of RNA of these three genes
were thought to be comparable to that of L-actin in synovio-
cytes stimulated with TNFK. FLJ10143 showed increased ex-
pression, and the amount of its RNA in the cells was thought
to be comparable to that of L-actin. IL8 is thought to play a
role in the in¢ltration by lymphoid cells [17]. TFPI2 is thought
to suppress ECM degradation in atheroma [18]. In smooth
muscle cells, TFPI2 acts as a mitogen [19]. PAI2 is an inhib-
itor of urokinase-type plasminogen activator and is thought to
contribute to local in£ammation [20]. Deaminated ¢brin, a
downstream product of PAI2-related reactions, was the
main target of RA-speci¢c autoantibodies [21]. These reported
functions of genes are consistent with the pathophysiology of
joints in RA. Thus, increased expression of these genes in
synoviocytes may play important roles in the early phase of
RA.
Other genes for which we demonstrated altered expression
also seem to be involved in the pathophysiology of RA. Ex-
pression of ICAM1 promoted in¢ltration by lymphoid cells
[22]. The chondroitin sulfate chain of ITIL increased in size
proportionally to the severity of the in£ammatory response
and was postulated to be involved in control of the in£am-
matory process [23]. PLOD-like protein, an enzyme involved
in collagen biosynthesis and its metabolism, was increased in
HTB-94 cells [15]. These genes might be involved in promo-
tion of the in£ammatory process. It was reported that lipid
pro¢les were altered in patients with RA [24]. The apolipo-
protein AI level was signi¢cantly higher in patients with RA
than in those with degenerative joint disease [25]. ARP1
down-regulated the expression of apolipoprotein AI [26],
known to suppress the production of TNFK [27]. TNFAIP3,
a nucleic acid binding protein, inhibited NF-UB-dependent
gene expression and apoptosis [28]. The decreased and in-
creased expression of ARPI and TNFAIP3, respectively,
might be a feedback system suppressing further in£ammation.
HLA-DRB1, a genotype known to be a risk factor of RA [29],
was increased in RA [30]. Its expression might relate to auto-
antigen presentation. It was reported that DPP2 activity was
higher, while DPP4 activity was lower, in synovial £uid of RA
patients compared with osteoarthritis patients [31]. We ob-
served a three-fold increase in DPP3 expression without any
change in DPP4 expression in the synoviocytes stimulated
with TNFK. DPP3 might also be related to the development
of pain by the degradation of enkephalin in the joints. These
reports represent various aspects of the pathophysiology of
RA. It was interesting that we observed all these changes in
synoviocytes stimulated with TNFK. Expression of these
genes in synoviocytes might be the basis of development of
RA.
A discrepancy between our results and those of previous
reports concerned the expression of nuclear protein ID1.
ID1 was reported to show increased expression in synovial
tissues of patients with RA [32]. However, we observed a
0.3-fold decrease in expression of ID1 in the synoviocytes
stimulated with TNFK. This di¡erence needs to be investi-
gated by other methods, such as Northern blot analysis.
The increased expression of ID1 observed in the in vivo study
might re£ect the more complicated features of RA compared
with the simple model of stimulation of synoviocytes with
TNFK.
In conclusion, we used statistical cDNA macroarray anal-
ysis to analyze the expression pro¢les of genes in synoviocytes
stimulated with TNFK. Our ¢ndings suggest that some of the
major functions of synoviocytes are the production of IL8,
TFPI2, PAI1 and FLJ10143 upon stimulation by TNFK.
The response of synoviocytes to TNFK stimulation may be
integral to the development of various aspects of the patho-
physiology of RA.
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